Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

French Drug Contract Tester Warned for GMP Violations

  • Post author:Sam
  • Post published:March 16, 2018
  • Post category:Drug Industry Daily

The FDA warned a French drug contract testing laboratory following a September inspection that revealed deficiencies in testing practices and discrepancy investigations. Source: Drug Industry Daily

Continue ReadingFrench Drug Contract Tester Warned for GMP Violations

AG Sessions’ Lexington Speech Outlines New Initiatives to Combat Opioid Crisis

  • Post author:Sam
  • Post published:March 16, 2018
  • Post category:Drug Industry Daily

Attorney General Jeff Sessions spoke in Lexington, Kentucky on Thursday, highlighting recently announced tools and programs geared towards fighting the U.S. opioid epidemic, including a team that will target online…

Continue ReadingAG Sessions’ Lexington Speech Outlines New Initiatives to Combat Opioid Crisis

New Analysis Says Payments From Opioid Makers Increase Doctors’ Likelihood to Prescribe Them

  • Post author:Sam
  • Post published:March 16, 2018
  • Post category:Drug Industry Daily

Doctors are five times more likely to prescribe a brand name drug if they receive payments from a pharmaceutical company for that drug, and the likelihood increases to 14.5 times…

Continue ReadingNew Analysis Says Payments From Opioid Makers Increase Doctors’ Likelihood to Prescribe Them

Arbor Biotechnologies Comes Out of Stealth Mode

  • Post author:Sam
  • Post published:March 15, 2018
  • Post category:BioPharma

Arbor Biotechnologies came out of stealth mode yesterday with a $15.6 million Series A financing round. Source: BioSpace

Continue ReadingArbor Biotechnologies Comes Out of Stealth Mode

Theranos Serves as a Cautionary Tale for Biotech Funding

  • Post author:Sam
  • Post published:March 15, 2018
  • Post category:BioPharma

There are dangers in biotech funding and Theranos should serve as a warning. Source: BioSpace

Continue ReadingTheranos Serves as a Cautionary Tale for Biotech Funding

FDA Gives Go-Ahead for Tetra's Phase II Trial

  • Post author:Sam
  • Post published:March 15, 2018
  • Post category:BioPharma

Tetra Discovery Partners announced that the FDA had given its Investigational New Drug application the go-ahead for Fragile X Syndrome and potentially other autism spectrum disorders. Source: BioSpace

Continue ReadingFDA Gives Go-Ahead for Tetra's Phase II Trial

What Astronaut Peggy Whitson Can Teach Us About Rejection in the Workplace

  • Post author:Sam
  • Post published:March 15, 2018
  • Post category:BioPharma

Peggy Whitson has spent 665 days in space, more than any other US astronaut and more than any other female astronaut in the world. You don’t associate Peggy Whitson with…

Continue ReadingWhat Astronaut Peggy Whitson Can Teach Us About Rejection in the Workplace

Johnson & Johnson Selling LifeScan Unit for $2.1 Billion

  • Post author:Sam
  • Post published:March 15, 2018
  • Post category:BioPharma

Platinum Equity submitted a binding offer to Johnson & Johnson to buy LifeScan for $2.1 billion. Source: BioSpace

Continue ReadingJohnson & Johnson Selling LifeScan Unit for $2.1 Billion

AMO Pharma Sees Positive Results in Phase II Trials

  • Post author:Sam
  • Post published:March 15, 2018
  • Post category:BioPharma

AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits such as an improvement in cognitive function and an…

Continue ReadingAMO Pharma Sees Positive Results in Phase II Trials

Adaptimmune Sees Positive Early Results in Cancer Treatment

  • Post author:Sam
  • Post published:March 15, 2018
  • Post category:BioPharma

Adaptimmune reported it saw three partial responses in three of the four myxoid/ round cell liposarcoma (MRCLS) patients the company dosed with its NY-ESO SPEAR T-cells. Source: BioSpace

Continue ReadingAdaptimmune Sees Positive Early Results in Cancer Treatment
  • Go to the previous page
  • 1
  • …
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.